This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutAboutClinical StudiesNonclinical StudyFeaturesDosing and AdministrationDosing and AdministrationGEL-FLOW NT Preparation StepsGEL-FLOW KIT Preparation StepsGEL-FLOW NT Preparation VideoSupport and OrderSupport and OrderMaterialsVideosOrdering Information
THROMBIN-JMI Prescribing InformationTHROMBIN-JMI and GEL-FLOW NT IndicationsGEL-FLOW NT Instructions for Use
A hemostatic standard of care1-7, IN A FLOWABLEGEL-FLOW KIT—NEXT GENERATION OF GELFOAM® (absorbable gelatin powder) & THROMBIN-JMI:
  • Provides variable viscosity levels based on surgical need8
  • Delivers 5,000 IU of thrombin in final flowable mixture9
  • Allows complete sterile field preparation8,9
Features Loading GEL-FLOW Preparation Steps Loading
GEL-FLOW NT 6 mL

Absorbable Gelatin Powder
Hemostatic Matrix for Flowable Applications

Learn more Loading
GEL-FLOW KIT 6 mL

GEL-FLOW™ NT Absorbable Gelatin Powder and Thrombin, Topical (Bovine) U.S.P., Thrombin-JMI®, 5,000 International Units Syringe Spray Kit

Learn more Loading

Please see full Prescribing Information, including BOXED WARNING, for THROMBIN-JMI.

Please see Instructions for Use for GEL-FLOW NT.

References:Doria C, Fischer CP, Wood CG, Li PM, Marra S, Hart J. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin. 2008;24(3):785-794. Evaluation of an absorbable surgical hemostatic agent: Thrombi-Gel® versus Gelfoam-thrombin (control). ClinicalTrials.gov website. NCT00652314. https://clinicaltrials.gov/ct2/show/NCT00652314. Accessed July 28, 2023. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007;205(2):256-265. Glickman M, Gheissari A, Money S, Martin J, Ballard JL; CoSeal Multicenter Vascular Surgery Study Group. A polymeric sealant inhibits anastomotic suture hole bleeding more rapidly than Gelfoam/thrombin: results of a randomized controlled trial. Arch Surg. 2002;137(3):326-331. Minkowitz H, Navarro-Puerto J, Lakshman S, et al; Clinical Investigation Study Group on Topical Thrombin (Human) Grifols in Surgery. Prospective, randomized, phase II, non-inferiority study to evaluate the safety and efficacy of topical thrombin (human) Grifols as adjunct to hemostasis during vascular, hepatic, soft tissue, and spinal open surgery. J Am Coll Surg. 2019;229(5):497-507.e1. Schreiber MA, Neveleff DJ. Achieving hemostasis with topical hemostats: making clinically and economically appropriate decisions in the surgical and trauma settings. AORN J. 2011;94(5):S1-S20.IMS data on file.GEL-FLOW NT (absorbable gelatin powder) [instructions for use]. New York, NY: Pfizer Inc.; 2022.THROMBIN-JMI (Thrombin, Topical [Bovine] U.S.P.) [prescribing information]. New York, NY: Pfizer Inc.; 2023.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-GFN-USA-0107
You are now leaving Pfizer
 
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-GFN-USA-0094
 
INDICATIONS THROMBIN-JMI

THROMBIN-JMI is topical bovine thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical.

In various types of surgeries, solutions of THROMBIN-JMI may be used in conjunction with an Absorbable Gelatin Sponge, USP for hemostasis.

Please see full Prescribing Information, including BOXED WARNING, for THROMBIN-JMI.

GEL-FLOW NT

GEL-FLOW NT is indicated in surgical procedures, including those involving cancellous bone bleeding, as a hemostatic device, when control of capillary, venous, and arteriolar bleeding by pressure, ligature, and other conventional procedures is either ineffective or impractical. Although not necessary, GEL-FLOW NT can be used either with or without thrombin to obtain hemostasis.

Please see Instructions for Use for GEL-FLOW NT.
Important Safety Information

THROMBIN-JMI

WARNING: SEVERE BLEEDING AND THROMBOSIS COMPLICATIONS

  • THROMBIN-JMI can cause fatal severe bleeding or thrombosis. Thrombosis may result from the development of antibodies against bovine thrombin. Bleeding may result from the development of antibodies against factor V. These may cross-react with human factor V and lead to its deficiency.
  • Do not re-expose patients to THROMBIN-JMI if there are known or suspected antibodies to bovine thrombin and/or factor V.
  • Monitor patients for abnormal coagulation laboratory values, bleeding, or thrombosis.
  • Do not inject directly into the circulatory system. Because of its action in the clotting mechanism, THROMBIN-JMI can cause extensive intravascular clotting or death.
  • Do not re-expose patients to THROMBIN-JMI if there are known or suspected antibodies to bovine thrombin and/or factor V.
  • Do not administer to patients with a history of hypersensitivity to THROMBIN-JMI, its components and/or to material of bovine origin.
  • Do not use for treatment of severe or brisk arterial bleeding.
  • Allergic reactions, including anaphylactic/anaphylactoid reactions, have been reported following administration of THROMBIN-JMI.
  • Institute intensive supportive measures and treat individual symptoms. Secure the airway and establish adequate respiratory exchange.
  • THROMBIN-JMI causes thrombosis if it enters the circulatory system. Apply topically. DO NOT INJECT.
  • ​Inhibitory antibodies may develop in patients and interfere with hemostasis. Monitor patients for abnormal coagulation laboratory values, bleeding, or thrombosis.

Most common adverse reactions (incidence greater than or equal to 2%) are hypersensitivity, bleeding, anemia, post-operative wound infection, thromboembolic events, hypotension, pyrexia, tachycardia and thrombocytopenia. Advise patients to consult their physician if they experience leg tenderness or swelling, chest pain, shortness of breath, or difficulty speaking or swallowing.

There is no human or animal data regarding use during pregnancy. It is also not known whether THROMBIN-JMI can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. THROMBIN-JMI should be given to a pregnant woman only if clearly needed.

Safety and effectiveness in children have not been established.

GEL-FLOW NT

GEL-FLOW NT should not be used in closure of skin incisions because it may interfere with healing of the skin edges. This is due to mechanical interposition of gelatin and is not secondary to intrinsic interference with wound healing.

GEL-FLOW NT must not be placed in intravascular compartments because of the risk of embolization.

Do not use GEL-FLOW NT in patients with known allergies to porcine collagen.

Life-threatening anaphylactic reactions, including death, have been reported after exposure to absorbable gelatin. Patients with history of allergies to porcine products may be at risk of serious acute hypersensitivity reactions, including anaphylaxis. If an anaphylactic reaction is observed, absorbable gelatin administration should be immediately discontinued and any applied product removed.

GEL-FLOW NT is not intended as a substitute for meticulous surgical technique and the proper application of ligatures, or other conventional procedures for hemostasis.

Unused, opened GEL-FLOW NT syringes or packs must be discarded. GEL-FLOW NT must not be resterilized.

Only the minimum amount of GEL-FLOW NT mixture necessary to achieve hemostasis should be used and applied to the bleeding site with pressure until bleeding stops. Once hemostasis is attained, excess GEL-FLOW NT mixture should be carefully removed.

The use of GEL-FLOW NT is not recommended in the presence of infection. GEL-FLOW NT should be used with caution in contaminated areas of the body.

The packing of GEL-FLOW NT, particularly within bony cavities, should be avoided, since swelling may interfere with normal function and/or possibly result in compression necrosis of surrounding tissues.

Whenever possible, GEL-FLOW NT should be removed after use in laminectomy procedures and from foramina in bone, once hemostasis is achieved. This is because GEL-FLOW NT may swell on absorbing fluids and produce nerve damage by pressure within confined bony spaces.

GELFOAM should not be placed in the vicinity of the cerebral ventricular space or where there is a possibility of a cerebrospinal fluid fistula to the target bleeding site. GELFOAM should also not be used as a tissue substitute to repair tissue defects of the dura or the cranium. GELFOAM may migrate from central nervous system cerebrospinal fluid surgical sites into the cerebral ventricular space and compromise the cerebrospinal fluid circulation. Hydrocephalus and cerebrospinal fluid retention, requiring a re-intervention to remove GELFOAM residue, have been reported in adult and pediatric patients. In some cases, these complications occurred several months after use of GELFOAM.

GEL-FLOW NT should not be used for controlling postpartum bleeding or menorrhagia.

GEL-FLOW NT should not be used in conjunction with autologous blood salvage circuits or methyl-methacrylate adhesives.

After placement, absorbable hemostatic agents may be visible on imaging studies until they are fully absorbed, which could be interpreted as pseudotumor/pseudomass appearance. Pseudoinfection/pseudoabscess has also been reported in the literature. Pseudotumor/pseudomass and pseudoinfection/pseudoabscess may result in additional invasive procedures, reoperations, and prolonged hospital stays.

There have been reports of the following events associated with the use of GELFOAM absorbable gelatin powder: fever (without demonstrated infection), infection, abscess formation, giant cell granuloma, CNS compression, foreign body reaction, encapsulation of fluid, hematoma, excessive fibrosis, prolonged fixation of a tendon, toxic shock syndrome, and hearing loss (in tympanoplasty surgeries).

In laminectomy operations, multiple neurologic events were reported, including but not limited to cauda equina syndrome, spinal stenosis, meningitis, arachnoiditis, headaches, paresthesias, pain, bladder and bowel dysfunction, and impotence.

Please see full Prescribing Information, including BOXED WARNING, for THROMBIN-JMI.

Please see Instructions for Use for GEL-FLOW NT.

IndicationSTHROMBIN-JMITHROMBIN-JMI is topical bovine thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical.​​​​​​In various types of surgeries, solutions of THROMBIN-JMI may be used in conjunction with an Absorbable Gelatin Sponge, USP for hemostasis.​​​​Please see full Prescribing Information, including BOXED WARNING, for THROMBIN-JMI.GEL-FLOW NTGEL-FLOW NT is indicated in surgical procedures, including those involving cancellous bone bleeding, as a hemostatic device, when control of capillary, venous, and arteriolar bleeding by pressure, ligature, and other conventional procedures is either ineffective or impractical. Although not necessary, GEL-FLOW NT can be used either with or without thrombin to obtain hemostasis.Please see Instructions for Use for GEL-FLOW NT.